Distinct outcome of stage I lung adenocarcinoma with ACTN4 cell motility gene amplification

Annals of Oncology

Volumn 24, Issue 10, 2013, Pages 2594-2600

  Noro, R ^a,b   Honda, K ^a   Tsuta, K ^c   Ishii, G ^a   Maeshima, A M ^c   Miura, N ^a   Furuta, K ^c   Shibata, T ^a   Tsuda, H ^c   Ochiai, A ^a   Sakuma, T ^d   Nishijima, N ^b   Gemma, A ^b   Asamura, H ^c   Nagai, K ^e   Yamada, T ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL   (Japan)

^d Mitsui Knowledge Industry Co   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Actinin 4 (ACTN4); Biomarker; Gene amplification; Lung neoplasm; Prognosis

Indexed keywords

ACTININ 4 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ACTININ 4 GENE; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CELL MOTILITY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE DOSAGE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MARKER GENE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY;

ACTININ-4 (ACTN4); BIOMARKER; GENE AMPLIFICATION; LUNG NEOPLASM; PROGNOSIS;

ACTININ; ADENOCARCINOMA; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884716592     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt293     Document Type: Article

References (25)

1. Bach PB, Kelley MJ, Tate RC et al. Screening for lung cancer: a review of the current literature. Chest 2003; 123: 72S-82S.
2. Manser RL, Irving LB, de Campo MP et al. Overview of observational studies of low-dose helical computed tomography screening for lung cancer. Respirology 2005; 10: 97-104.
3. Aberle DR, Adams AM, Berg CD et al. Reduced lung-cancer mortality with lowdose computed tomographic screening. N Engl J Med 2011; 365: 395-409.
4. Goya T, Asamura H, Yoshimura H et al. Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 2005; 50: 227-234.
5. Honda K, Yamada T, Endo R et al. Actinin-4, a novel actin-bundling protein associated with cell motility and cancer invasion. J Cell Biol 1998; 140: 1383-1393.
6. Honda K, Yamada T, Hayashida Y et al. Actinin-4 increases cell motility and promotes lymph node metastasis of colorectal cancer. Gastroenterology 2005; 128: 51-62.
7. Hayashida Y, Honda K, Idogawa M et al. E-cadherin regulates the association between beta-catenin and actinin-4. Cancer Res 2005; 65: 8836-8845.
8. Kikuchi S, Honda K, Tsuda H et al. Expression and gene amplification of actinin-4 in invasive ductal carcinoma of the pancreas. Clin Cancer Res 2008; 14: 5348-5356.
9. Barbolina MV, Adley BP, Kelly DL et al. Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest 2008; 88: 602-614.
10. Yamada S, Yanamoto S, Yoshida H et al. RNAi-mediated down-regulation of alphaactinin- 4 decreases invasion potential in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 2010; 39: 61-67.
11. Welsch T, Keleg S, Bergmann F et al. Actinin-4 expression in primary and metastasized pancreatic ductal adenocarcinoma. Pancreas 2009; 38: 968-976.
12. Yamamoto S, Tsuda H, Honda K et al. Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. Mod Pathol 2007; 20: 1278-1285.
13. Yamagata N, Shyr Y, Yanagisawa K et al. A training-testing approach to the molecular classification of resected non-small cell lung cancer. Clin Cancer Res 2003; 9: 4695-4704.
14. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
15. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3: 203-216.
16. Yamamoto S, Tsuda H, Honda K et al. Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance. Mod Pathol 2009; 22: 499-507.
17. Ost D, Goldberg J, Rolnitzky L et al. Survival after surgery in stage IA and IB nonsmall cell lung cancer. Am J Respir Crit Care Med 2008; 177: 516-523.
18. Anami Y, Takeuchi T, Mase K et al. Amplotyping of microdissected, methanol-fixed lung carcinoma by arbitrarily primed polymerase chain reaction. Int J Cancer 2000; 89: 19-25.
19. WolffAC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
20. Pisters KM, Evans WK, Azzoli CG et al. Cancer Care Ontario and American Society of Clinical Oncology adjuvant chemotherapy and adjuvant radiation therapy for stages I-IIIA resectable non small-cell lung cancer guideline. J Clin Oncol 2007; 25: 5506-5518.
21. Arriagada R, Bergman B, Dunant A et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350: 351-360.
22. Douillard JY, Rosell R, De Lena M et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7: 719-727.
23. Winton T, Livingston R, Johnson D et al. Vinorelbine plus cisplatin versus observation in resected non-small-cell lung cancer. N Engl J Med 2005; 352: 2589-2597.
24. Kato H, Ichinose Y, Ohta M et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350: 1713-1721.
25. Strauss GM, Herndon JE, II, Maddaus MA et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008; 26: 5043-5051.